Case Type: Mergers & Acquisitions

Sumo Logic, Inc. (NASDAQ: SUMO), relating to its proposed sale to affiliates of Francisco Partners. Under the terms of the agreement, SUMO shareholders are expected to receive $12.05 in cash per share they own.

Oak Street Health, Inc. (NYSE: OSH), relating to its proposed sale to CVS Health. Under the terms of the agreement, OSH shareholders are expected to receive $39.00 in cash per share they own.

Argo Group International Holdings, Ltd. (NYSE: ARGO), relating to its proposed sale to Brookfield Reinsurance. Under the terms of the agreement, ARGO shareholders are expected to receive $30.00 in cash per share they own

AlerisLife Inc. (NASDAQ: ALR), relating to its proposed sale to APB Acquisition LLC. Under the terms of the agreement, ALR shareholders are expected to receive $1.31 in cash per share they own.

Chembio Diagnostics, Inc. (NASDAQ: CEMI), relating to its proposed sale to Biosynex SA. Under the terms of the agreement, CEMI shareholders are expected to receive $0.45 in cash per share they own.

Atlas Technical Consultants, Inc. (NASDAQ: ATCX), relating to its proposed sale to GI Partners. Under the terms of the agreement, ATCX shareholders are expected to receive $12.25 in cash per share they own.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), relating to its proposed acquisition by Sun Pharmaceutical Industries Limited. Under the terms of the tender offer, CNCE shareholders are expected to receive $8.00 in cash and one non-tradeable CVR worth a deferred $3.50 in cash per share they own.

Leap Therapeutics, Inc. (NASDAQ: LPTX), relating to its proposed purchase of Flame Biosciences, Inc. Under the terms of the agreement, LPTX will issue shares of common stock and Series X non-voting convertible preferred stock to Flame shareholders, with each Series X share convert to 1000 shares of common stock upon approval of the transaction.

Volta Inc. (NYSE: VLTA), relating to its proposed sale to Shell USA. Under the terms of the agreement, VLTA shareholders are expected to receive $0.86 in cash per share they own.

Calyxt, Inc. (NASDAQ: CLXT), relating to its proposed merger with Cibus. Under the terms of the agreement, Cibus shareholders are expected to receive new shares of CLXT, with CLXT shareholders expected to own approximately 5% of the combined company.